Zynex, Inc. (NASDAQ: ZYXI ) Q4 2024 Earnings Conference Call: Key Insights
On March 11, 2025, at 4:15 PM ET, Zynex, Inc. (NASDAQ: ZYXI ) held its Q4 2024 earnings conference call. The call was led by Brian Prenoveau, Investor Relations, Thomas Sandgaard, Chairman of the Board, President, and Chief Executive Officer, Dan Moorhead, Chief Financial Officer, and Anna Lucsok, Chief Operating Officer. Donald Gregg, President of Zynex Monitoring Solutions, was also present.
Financial Highlights
During the call, Zynex announced its financial results for the fourth quarter and full year ended December 31, 2024. The company reported a 15% increase in revenue for Q4 2024, totaling $35.5 million, compared to $30.8 million in the same period the previous year. For the full year 2024, Zynex reported a revenue of $129.8 million, representing a 12% increase from $116.2 million in 2023.
Operational Updates
Thomas Sandgaard discussed the company’s operational progress, highlighting the expansion of its product offerings and geographic reach. Zynex has launched several new products in 2024, including the NeuroMove system, which provides functional electrical stimulation for stroke patients, and the Zynex Vital Signs System, which offers remote patient monitoring capabilities. The company has also expanded its presence in Europe, the Middle East, and Africa.
Impact on Investors
Jeffrey Cohen of Ladenburg Thalmann and H.C. Wainwright & Co.’s Chen asked about the potential impact of Zynex’s growth on its financial performance and valuation. Dan Moorhead responded by stating that the company expects to continue its revenue growth in the mid-teens percentage range in 2025, driven by the expansion of its product portfolio and geographic reach. He also mentioned that the company is exploring potential strategic acquisitions to further boost growth.
Impact on Healthcare Industry
The healthcare industry is expected to benefit significantly from Zynex’s innovative solutions, particularly in the areas of remote patient monitoring and functional electrical stimulation. The growing aging population and the increasing prevalence of chronic conditions are creating a significant demand for remote patient monitoring systems. Zynex’s NeuroMove system, for instance, can help stroke patients regain mobility and improve their quality of life. The company’s solutions can also help healthcare providers reduce costs by enabling remote patient care and reducing hospital readmissions.
Conclusion
Zynex, Inc.’s Q4 2024 earnings conference call provided valuable insights into the company’s financial performance and operational progress. The company’s revenue growth, new product launches, and geographic expansion are expected to continue driving its financial performance in 2025. Moreover, Zynex’s innovative solutions can have a significant impact on the healthcare industry by improving patient outcomes and reducing costs. Investors and industry stakeholders should closely monitor Zynex’s progress as it continues to expand its product offerings and geographic reach.
- Zynex reported a 15% increase in revenue for Q4 2024, totaling $35.5 million.
- The company’s revenue for the full year 2024 was $129.8 million, representing a 12% increase from 2023.
- Zynex has launched several new products, including the NeuroMove system and the Zynex Vital Signs System.
- The company has expanded its presence in Europe, the Middle East, and Africa.
- Zynex expects to continue its revenue growth in the mid-teens percentage range in 2025.
- Zynex’s solutions can improve patient outcomes and reduce costs in the healthcare industry.
